[Large-scale production of recombinant adeno-associated virus (rAAV)]

Abstract

Recombinant adeno-associated virus has been proven to be a promising gene delivery vector for human gene therapy with many advantages. Successful applications of recombinant adeno-associated virus vectors in preclinical and clinical human gene therapies make it become a demanded product. A well-established and large-scale production system is therefore required. Since wild type of adeno-associated virus was well characterized in 1989, progress has been made. Particularly, package system of recombinant adeno-associated virus has been developed to use insect cell instead of human cell. These advances in adeno-associated virus production will allow it to meet the demands of basic research and clinical applications. This review will focus on trends in packaging systems and development on a large scale of recombinant adeno-associated virus production.